Not Signed In -
Hepatitis B Vaccine |
Engerix-B; Recombivax HB |
Clinical Trial: Study of an Investigational Vaccine in Healthy Infants in Taiwan
This study is no longer recruiting patients.
|
Purpose
The purpose of this study is to evaluate the safety, tolerability, and immune response of an investigational vaccine being evaluated to reduce the incidence of diphtheria, pertussis, tetanus, hepatitis B, poliomyelitis, and Haemophilus influenza type b.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Diphtheria Tetanus Pertussis Hepatitis B Poliomyelitis | Vaccine: Investigational Vaccine | Phase II Phase III |
MedlinePlus related topics: Bacterial Infections; Bronchitis; Diphtheria; Hepatitis B; Polio and Post-Polio Syndrome; Respiratory Diseases; Tetanus
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title: A Study of the Safety, Tolerability, and Immunogenicity of an Investigational Vaccine in Healthy Infants in Taiwan
Eligibility
Ages Eligible for Study: 6 Weeks - 8 Weeks, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Healthy infant who received Hepatitis B vaccine within 5 days of birth and whose mother is negative to Hepatitis B surface antigen
Exclusion Criteria:
- Problems with immune system
- Recent illness with fever
Location Information
Pennsylvania
Call for International Site Information, Horsham, Pennsylvania, 19044, United States
More Information
Record last reviewed: September 2004
Last Updated: October 13, 2004
Record first received: September 22, 2004
ClinicalTrials.gov Identifier: NCT00092469
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Engerix-B (Drug Digest)
- Hepatitis B Vaccine (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
